Positive predictive value of CEA and Ca19-9 as tumor markers for recurrent colorectal cancer in cases where conventional work-up fail to localize disease.
Abstract
Introduction: Routine surveillance of colorectal cancer includes serial measurements of CEA levels. Although not routinely indicated Ca 19-9 is also a tool for recurrence. When any of these serum markers is elevated during follow up, this could represent a recurrence. The management of elevated tumor marker levels include clinical exams, endoscopy and conventional imaging –ultrasound, CT, MRI.
Objective: To evaluate the positive predictive value of CEA and Ca19-9 as tumor markers for recurrent colorectal cancer in cases where conventional imaging and endoscopic studies fail to localize disease.
Materials and methods: A total of 75 patients with elevated CEA and/or Ca19-9 serum levels and negative endoscopic exam as well as negative abdominal CT and Chest X-ray were included in the study. CEA levels were tested in 50 patients. Ca 19-9 was tested in 65 patients. 34 of the patients had both markers tested. All patients underwent whole body 18F-FDG PET/CT. Patients with negative of equivocal PET scan were further followed up (10 to 24 months).
Results: Based on the reference standard – the results from PET/CT, if positive and the results from follow-up in cases of negative or equivocal scans, the positive predictive value of Ca 19-9 was 84% and that of CEA -83%. There was no significant difference in the PPV of Ca19-9 and CEA.
Conclusion: Elevated CEA and Ca 19-9 levels in patients under active surveillance after operation for colorectal cancer have high positive predictive value for recurrence, even in cases where conventional work-up – endoscopy and CT don’t localize disease.
References
Abir,F.,Alva,S.,Longo,W.Audiso,R.,Virgo,KS.,Johnson,FE. (2006) The postoperative surveillance of patients with colon cancer and rectal cancer. Am J Surg,192(1):100-108
Del Villano,BC.,Brennan,S.,Brock,P.,Bucher,C.,Liu,V.,McClure,M.,Rake,B.,Space,S.,Westrick,B., Schoemaker,H.,Zurawski,VR Jr. (1983) Radioimmunometric assay for monoclonal antibody-defined tumor marker, CA19-9. Clinical Chemistry, 29;549-552
Diez,M.,Cerdán,FJ.,Pollán,M.,Maestro,ML.,Ortega,MD.,Martínez,S.,Moreno,G.,Balibrea,JL. (1994) Prognostic significance of preoperative serum CA 19-9 assay in patients with colorectal carcinoma. Anticancer Research,14: 2819-26
Duffy,MJ.,van Dalen,A.,Haglund,C.,Hansson,L.,Holinski-Feder,E.,Klapdor,R.,Lamerz,R.,Peltomaki,P., Sturgeon,C.,Topolcan,O. (2007) Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use . European Journal of cancer 43:1348-1360.
Figueredo,A.,Rumble,RB.,Maroun,J,Earle,CC,Cummings,B,McLeod,R.,Zuraw,L.,Zwaal,C. (2003) Follow-up of patients with curatively resected colorectal cancer: A practice guideline. BMC Cancer, 3:26
Fiocchi, F., Iotti,V., Ligabue,G., Malavasi,N., Luppi,G,, Bagni,B.,Torricelli,P. (2011) Role of carcinoembryonic antigen, magnetic resonance imaging, and positron emission tomography-computed tomography in the evaluation of patients with suspected local recurrence of colorectal cancer. Clinical Imaging, 35: 266–273
Grossmann,I.de Bock,GH.,Meershoek-Klein Kranenbarg,WM.,van de Velde,CJ.,Wiggers, T. (2007) Carcinoembryonic antigen (CEA) measurement during follow-up for rectal carcinoma is useful even if normal levels exist before surgery. A retrospective study of CEA values in the TME trial. European Journal of Surgical oncology.33(2):183-187
In Ja Park, Gye-Seog Choi, Soo Han Jun (2009) Prognostic Value of Serum Tumor Antigen CA19-9 After Curative Resection of Colorectal Cancer. Anticancer research, 29: 4303-4308
Jemal,A.,Bray,F.,Center,MM.,Ferlay,J.,Ward,E.,Forman,D.(2011) Global cancer statistics. Ca Cancer J Clin, 61:69-90
Kawamura,YJ.,Tokumitsu,A.,Mizokami,K.,Sasaki,J.,Tsujinaka,S.,Konishi,F.(2010)First Alert for Recurrence During Follow-up After Potentially Curative Resection for Colorectal Carcinoma: CA 19-9 Should Be Included in Surveillance Programs. Clinical Colorectal Cancer, 9(1):48-51
Kim B.J., Lee, K.T.,Moon, T.G. (2009) How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects? Digestive and Liver Disease,41: 364–369
Koprovski,H., Steplewski,Z.,Mitchell,K.,Herlin,M.,Fuhrer,P. (1979) Colorectal carcinoma antigen detected by hybridoma antibodies. Somatic Cell Genetics, 5:957-72/
Magnani, JL., Nilsson, B., Brockhaus, M., Zopf, D., Steplewski, Z., Koprowski, H., Ginsburg, V. (1982) A monoclonal antibody-defined antigen associated with gastrointestinal cancer in a ganglioside containing sialylated lacto N- fucopentaose II, J Biol Chem,257:14365-9
Metser, U., You,J., McSweeney,S., Freeman,M., Hendler,A. (2010) Assessment of Tumor Recurrence in Patients With Colorectal Cancer and Elevated Carcinoembryonic Antigen Level: FDG PET/CT Versus Contrast-Enhanced 64-MDCT of the Chest and Abdomen. American Journal of roentgenology, 194(3):766-71
NCCN clinical practice guidelines in oncology – Colon Cancer v.3/2015. Retrieved Aug, 6, 2015, from http://www.nccn.org/professionals/physician_gls/pdf/colon.pdf
NCCN clinical practice guidelines in oncology – Rectal Cancer v.3/2015. Retrieved Aug, 6, 2015, from http://www.nccn.org/professionals/physician_gls/pdf/rectal.pdf
Nicolini,A., Ferrari,P., Duffy,MJ., Antonelli,A., Rossi,G., Metelli,MR.,Fulceri,F.,Anselmi,L.,Conte,M., Berti,P., Miccoli,P.(2010)Intensive Risk-Adjusted Follow-up With the CEA,TPA, CA19.9, and CA72.4 Tumor Marker Panel and Abdominal Ultrasonography to Diagnose Operable Colorectal Cancer Recurrences. Archives of surgery,145(12):1177-83
Obrand,D.,Gordon,P. (1997) Incidence and pattern of recurrence following curative resection for colorectal carcinoma. Diseases of the colon and rectum, 40(1): 15-24
Renehan,AG.,Egger,M.,Saunders,MP.,O'Dwyer,ST. (2002) Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ, 324:813.
Tan, E., Gouvas, N., Nicholls, RJ., Ziprin, P., Xynos, E., Tekkis, PP. (2009). Diagnostic precision of carcinoembryonic antigenin the detection of recurrence of colorectal cancer . Surgical Oncology ,18: 15-24
Thomas L (1998). Clinical Laboratory Diagnostics; TH Books, Frankfurt/Main
Copyright information
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (Creative Commons Attribution License 3.0 - CC BY 3.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
info@cbuni.cz, www.cbuni.cz, ojs.journals.cz
